JP2021512109A - スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 - Google Patents

スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 Download PDF

Info

Publication number
JP2021512109A
JP2021512109A JP2020541807A JP2020541807A JP2021512109A JP 2021512109 A JP2021512109 A JP 2021512109A JP 2020541807 A JP2020541807 A JP 2020541807A JP 2020541807 A JP2020541807 A JP 2020541807A JP 2021512109 A JP2021512109 A JP 2021512109A
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
compound according
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512109A5 (https=
Inventor
カーン，エム．，アミン
Original Assignee
アプティニックス インコーポレイテッド
アプティニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプティニックス インコーポレイテッド, アプティニックス インコーポレイテッド filed Critical アプティニックス インコーポレイテッド
Publication of JP2021512109A publication Critical patent/JP2021512109A/ja
Publication of JP2021512109A5 publication Critical patent/JP2021512109A5/ja
Priority to JP2023192455A priority Critical patent/JP2024019396A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020541807A 2018-01-31 2019-01-31 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 Pending JP2021512109A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192455A JP2024019396A (ja) 2018-01-31 2023-11-10 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US62/624,218 2018-01-31
US201862718107P 2018-08-13 2018-08-13
US62/718,107 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192455A Division JP2024019396A (ja) 2018-01-31 2023-11-10 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用

Publications (2)

Publication Number Publication Date
JP2021512109A true JP2021512109A (ja) 2021-05-13
JP2021512109A5 JP2021512109A5 (https=) 2022-02-01

Family

ID=65494516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541807A Pending JP2021512109A (ja) 2018-01-31 2019-01-31 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
JP2023192455A Withdrawn JP2024019396A (ja) 2018-01-31 2023-11-10 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192455A Withdrawn JP2024019396A (ja) 2018-01-31 2023-11-10 スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用

Country Status (15)

Country Link
US (1) US20210047324A1 (https=)
EP (1) EP3746442A1 (https=)
JP (2) JP2021512109A (https=)
KR (1) KR20200115610A (https=)
CN (1) CN112218866A (https=)
AU (1) AU2019215049A1 (https=)
BR (1) BR112020015666A2 (https=)
CA (1) CA3089559A1 (https=)
CL (1) CL2020001990A1 (https=)
IL (1) IL276330A (https=)
MX (1) MX2020008106A (https=)
PE (1) PE20211455A1 (https=)
PH (1) PH12020551140A1 (https=)
SG (1) SG11202007251XA (https=)
WO (1) WO2019152678A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
AU2024354932A1 (en) * 2023-10-03 2026-04-09 Revolution Medicines, Inc. Synthesis of ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011013785A1 (ja) * 2009-07-31 2011-02-03 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2011100585A1 (en) * 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
EP2951186B1 (en) * 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9758525B2 (en) * 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2016506962A (ja) * 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
KR102410989B1 (ko) * 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
PE20151416A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
MX379622B (es) * 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
KR102465758B1 (ko) * 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011013785A1 (ja) * 2009-07-31 2011-02-03 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
J. ORG. CHEM., vol. 76(9), JPN6022052697, 2011, pages 3381 - 3391, ISSN: 0005104253 *
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 21(2), JPN7022005780, 1984, pages 583 - 586, ISSN: 0005104255 *
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 40(4), JPN7022005787, 2003, pages 557 - 563, ISSN: 0005104256 *
RESISTRY(STN)[ONLINE], JPN7022005781, ISSN: 0005104257 *
RESISTRY(STN)[ONLINE], JPN7022005782, ISSN: 0005104258 *
RESISTRY(STN)[ONLINE], JPN7022005783, ISSN: 0005104259 *
RESISTRY(STN)[ONLINE], JPN7022005784, ISSN: 0005104260 *
RESISTRY(STN)[ONLINE], JPN7022005785, ISSN: 0005104261 *
RESISTRY(STN)[ONLINE], JPN7022005786, ISSN: 0005104262 *
SYNLETT, vol. (12), JPN7022005779, 2005, pages 1865 - 1868, ISSN: 0005104254 *

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
WO2019152678A1 (en) 2019-08-08
IL276330A (en) 2020-09-30
MX2020008106A (es) 2020-09-25
PE20211455A1 (es) 2021-08-05
CA3089559A1 (en) 2019-08-08
BR112020015666A2 (pt) 2021-02-23
KR20200115610A (ko) 2020-10-07
US20210047324A1 (en) 2021-02-18
JP2024019396A (ja) 2024-02-09
CL2020001990A1 (es) 2021-03-26
SG11202007251XA (en) 2020-08-28
CN112218866A (zh) 2021-01-12
PH12020551140A1 (en) 2021-05-31
EP3746442A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
JP2021512109A (ja) スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US10273239B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
EP2951185B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CN105229011B (zh) 螺‑内酰胺nmda受体调节剂及其用途
CN105408336B (zh) 螺-内酰胺nmda受体调节剂及其用途
CN109843889B (zh) 螺-内酰胺nmda调节剂和使用其的方法
CN109661398B (zh) 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CN109890825B (zh) 螺-内酰胺nmda受体调节剂及其用途
JP2021512098A (ja) スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2019152696A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2024054919A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2019152681A1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240130